Jp Solar Vasconcelos retweeted
Safety & efficacy of INCB161734, a oral KRAS G12D inh, in combination with GEMNab or FOLFIRINOX in mPDAC
#ESMO26 #ESMOAmbassadors
👉ORR: 69 vs 89%, no PD
👉mPFS:
👉GI & hemato toxicity, but no skin tox
🧐very impressive, combination with both CTx feasible, ph 3 ongoing
@myESMO @ASCO
Jp Solar Vasconcelos retweeted
Ooo, supportive care. Easy win for patients.
Looks like swapping olanzapine out for mirtazapine significantly reduces nausea. Relevant to every oncologist.
Randomized trial from India at #ESMO26. 120 chemo-naive patients starting highly emetogenic chemo, randomized 1:1. Both arms got fosaprepitant + palonosetron + dex. Fourth drug was mirtazapine 15 mg vs olanzapine 5 mg, days 1–4.
Mirtazapine vs olanzapine:
Acute 78.5% vs 56.4%, p=0.01
Delayed 52.3% vs 25.5%, p=0.003
Overall 46.2% vs 21.8%, p=0.005
Major differences
120 patients? Minimal risk? I'm sold. The day after the paper comes out, I'll swap.
@realbowtiedoc thoughts?
@OncoAlert @TheGutOncLab @Onco_Nexus
Jp Solar Vasconcelos retweeted
LEAP-012 study of lenvatinib + pembrolizumab vs plc with TACE for HCC: Long-term OS results
#ESMO26 #ESMOAmbassadors
👉ORR: 48 vs 33.7%
👉 mPFS: 14.6 vs 10.2 mo
👉 mOS: 40.4 vs 40.8 mo
🧐 Higher ORR & PFS did not translate into OS, a bit disappointing
@myESMO @ASCO
Jp Solar Vasconcelos retweeted
🚨 RECTAL CANCER WITHOUT CHEMO, RADIATION OR SURGERY?
🌍 AZUR-1 | #ESMO26
📖 Concomitant publication in Annals of Oncology!
Dostarlimab in 154 patients with stage II/III dMMR/MSI-H rectal cancer:
🔥 68% sustained clinical CR ≥12 months
🔥 76% sustained cCR + pCR
🔥 98% maintained cCR ≥12 months
✅ No recurrences reported among patients achieving cCR/pCR!
💡 Could immunotherapy make organ preservation the new standard?
⚠️ Single-arm interim results; central review remains immature.
@myesmo @ESMO_open @ASCO @oncoalert
#ESMO26 #RectalCancer #Immunotherapy
🚨 ESMO 2026 | TOP 10 GI CANCER TRIALS TO WATCH!
From CLDN18.2 ADCs and PD-1/VEGF bispecifics to chemotherapy-free strategies, major GI oncology data are coming at #ESMO26!
🔥 My Top 10 Trials
🔴 GASTRIC / GEJ CANCER
CLARITY-Gastric 01 (LBA7) | CLDN18.2 ADC vs investigator’s choice
G-HOPE-001 (LBA77) | Novel CLDN18.2 ADC
HERIZON-GEA-01 (LBA79) | Zanidatamab + chemotherapy ± tislelizumab
GERCOR-GONO DEWI | Dostarlimab and nonoperative management in dMMR disease
LOMAC (LBA81) | 4 vs 6 months of adjuvant CAPOX
KC-WISE (LBA80) | Anbenitamab + chemotherapy
RAMIRIS | FOLFIRI + ramucirumab vs paclitaxel + ramucirumab
FORTITUDE-101/102 | FGFR2-targeted therapy and biomarker analysis
🟠 BILIARY TRACT CANCER
HARMONi-GI1 (LBA8) | Ivonescimab + chemotherapy vs durvalumab + chemotherapy
🟣 ESOPHAGEAL / GEJ CANCER
KEYNOTE-975 (2875O) | Pembrolizumab + definitive chemoradiotherapy
⭐ Two Presidential trials to watch closely: CLARITY-Gastric 01 and HARMONi-GI1.
Which GI trial will have the greatest clinical impact?
@myesmo @ESMO_open @ASCO @oncoalert
#ESMO26 #GICancer #Oncology
Jp Solar Vasconcelos retweeted
#ESMO26 | IROCAS
I think we can finally put this debate to rest
In high-risk stage III colon cancer, intensifying adjuvant chemotherapy with mFOLFIRINOX failed to improve DFS over mFOLFOX6
We need to rethink our approach to treatment escalation in the adjuvant setting. Simply adding more conventional cytotoxic agents is not the answer.
Jp Solar Vasconcelos retweeted
AZUR-1 delivers. #ESMO26
Phase 2, single arm. Dostarlimab x 9 cycles (6 months) in untreated stage II/III dMMR/MSI-H rectal cancer, 154 patients.
Cercek's 49-patient NEJM cohort gone global.
No control arm, because randomizing these patients to TNT/TME isn't equitable.
cCR12 (complete response held 12+ months, no further treatment):
68% by investigator.
26% needed additional treatment
10% went to surgery
68% is likely lower than reality since many patients probably just needed more time to radiographically respond. Using PET/Biopsy/ctDNA, especially ctDNA, is incredibly helpful in my practice to identify patients who can avoid TME even if a fibrotic tumor remains as they often do.
FDA already gave accelerated approval (way to steal the ESMO thunder) last week which leads me to my next point.
Obvious new standard of care. You should go to oncology jail if you don't treat MSI-H with IO.
@OncoAlert @TheGutOncLab @Onco_Nexus
Jp Solar Vasconcelos retweeted
☢️ MASTERPLAN - randomised Phase 2 (Lancet Oncology)
This is the clearest randomized evidence so far that ablative-range neoadjuvant SBRT after modern chemo decreases locoregional recurrence.
🎯 High-risk localised PDAC: >4 cm, node-positive, borderline or LAPC
💊 mFOLFIRINOX or gem–nab-paclitaxel ± SBRT 40 Gy/5 fx
👥 74 patients, closed early (120 planned)
📉 12-mo locoregional recurrence 20.2% vs 52.0%, sHR 0.44
➖ Grade ≥3 AEs 70% vs 64%
⚠️ No survival endpoint reported
Why did it close early ? slow accrual.
Powered for PFS and OS: no.
Radiotherapy in pancreatic cancer has a long history of trials that improved local control without moving survival. (when I say long I mean at least: PREOPANC-1 and 2, Alliance A021501, ESPAC-5, PANDAS-PRODIGE 44, CONKO-007, LAP07, SABER... )
MASTERPLAN shows modern SBRT, layered onto mFOLFIRINOX or gem–nab-paclitaxel, more than halves 12m locoregional recurrence without a clear toxicity penalty.
For borderline and locally advanced patients where local failure drives symptoms, this is a strong argument for SBRT in the multidisciplinary plan, but not yet proof it changes survival.
#PDAC #PancreaticCancer #SBRT #RadOnc #GIOnc
thelancet.com/journals/lanon…
Jp Solar Vasconcelos retweeted
🔥Presidential session at ESMO 2026 🔥
HARMONi-GI1 ph-3: Ivonescimab + CTx vs durvalumab + CTx as 1L for BTC
#ESMO26 #ESMOAmbassadors
👉ORR: 53.8 vs. 32.5 %
👉mPFS: 8.4 vs 5.8 mo
👉mOS: 14.9 vs. 12.1 mo
🧐 Very promising Chinese data, would be great to see data in a global population
@myESMO @ASCO
Jp Solar Vasconcelos retweeted
PRABITAS phase III trial pragmatic trial enrolled 972 pts in 17M evaluating the schedule of TAS-102 + bev (2 weeks on/2 weeks off) vs. (1 week on/1 week off) which validates non-inferiority and less dose reductions validating our RWD approach in the US. #colorectal #cancer #ESMO2026 @OncoAlert
Jp Solar Vasconcelos retweeted
ESMO 2026 presidential 2 | HARMONi-GI1: Ivonescimab beats durvalumab in advanced biliary tract cancer!
Phase III trial (n=682): Ivonescimab (PD-1/VEGF bispecific antibody) + gemcitabine/cisplatin vs durvalumab + gemcitabine/cisplatin in 1L advanced BTC.
📊 Key results:
✅ Median OS: 14.9 vs 12.1 months (HR 0.75; p=0.0031)
✅ Median PFS: 8.4 vs 5.8 months (HR 0.61; p<0.0001)
✅ ORR: 53.8% vs 32.5% (p<0.0001)
✅ Manageable safety profile; no new safety signals.
🔥 25% reduction in risk of death and 39% reduction in risk of progression!
A rare head-to-head phase III victory against an established immunotherapy standard in BTC.
Could PD-1/VEGF bispecific antibodies replace conventional PD-L1 inhibition in first-line BTC? @OncoAlert @myESMO
#ESMO26 #BiliaryTractCancer #Oncology
Jp Solar Vasconcelos retweeted
Shout out to the PRABITAS study team 🇯🇵 for providing Level 1 evidence to confirm earlier RWE (with a pragmatic design and no industry funding!)
➡️ biweekly TAS102 should be the new standard for SUNLIGHT
➡️Simultaneous publication in @TheLancet
thelancet.com/journals/lance…
➡️Great discussion by @KaiKeenShiu
#ESMO26 @myESMO
Biweekly vs conventional trifluridine/tipiracil plus bevacizumab for refractory mCRC: The pragmatic ph 3 PRABITAS trial
#ESMO26 #ESMOAmbassadors
👉ORR: 2 vs 2%
👉 mPFS: 3.9 vs 3.9 mo
👉 mOS: 10.3 vs 11.3 mo
🧐similar efficacy, less toxicity, supports biweekly schedule
@myESMO @ASCO
Jp Solar Vasconcelos retweeted
ACTICCA-1 trial: Adj. GemCis vs standard of care after curative intent resection of BTC
#ESMO26 #ESMOAmbassadors
👉 DFS at 2yrs: 52 vs 44%
👉mDFS: 23.3 vs 20.6
👉 mOS: 58 vs 48 mo
👉expected toxicity for the doublet
🧐 Trend for OS benefit, not an option for all, but may be considered as option for selected pts
@myESMO @ASCO
Jp Solar Vasconcelos retweeted
Final OS results from CheckMate 8HW: Nivo plus ipi vs nivo or CTx in MSI-H/dMMR mCRC
#ESMO26 #ESMOAmbassadors
👉ORR 72% 58%
👉mOS: NR --> NI vs N HR 0.66
👉5-yr for Nivo/Ipi: 77%
🧐Convincing, Nivo + Ipi as SOC in 1L MSI CRC
@myESMO @ASCO
Jp Solar Vasconcelos retweeted
Encorafenib plus cetuximab beyond progression in combination with FOLFIRI in BRAF V600E mCRC progressing on EC: Results from the ECLYPse phase II trial
#ESMO26 #ESMOAmbassadors
👉 mPFS: 7.1
👉 mOS: NR
👉ORR 15%
🧐Interesting signal to continue EC, more translational data would be great
@myESMO @ASCO
Jp Solar Vasconcelos retweeted
DFS and OS after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-arm, multicentre, phase 2, NICHE-2 trial
@TheLancet
doi.org/10.1016/S0140-6736(2…
👉💯% DFS
👉💯% OS
👏does not need any comment
@myESMO @ASCO
Jp Solar Vasconcelos retweeted
#ESMO26 | LBA31
PRABITAS: Pragmatic Ph3 biweekly FTD/TPI + bev vs conventional FTD/TPI + bev in mCRC (non-inferiority)
▪️OS: 11.3 vs 10.3 mo, HR 0.93, 95% CI 0.80-1.08 (<1.25)
▪️PFS: 3.9 vs 3.9 mo, HR 0.93, 95% CI 0.81-1.06
▪️Safety
- ≥G3 neutropenia: 13% vs 39%
- FN: 1% vs 5%
- ≥G2 anorexia: 15% vs 26%
👉Biweekly FTD/TPI + bev showed non-inferior OS with less toxicities!
@myESMO @OncoAlert
Jp Solar Vasconcelos retweeted
ATM rarely confers sensitivity to PARPi. But it does confer sensitivity to TOPO1 inhibitors. 👉🔥🎯
link.springer.com/article/10…
Jp Solar Vasconcelos retweeted
🔥AGITG MASTERPLAN🔥
Borderline resectable or Locally advanced PDAC
n=75
🔍Randomized
3m mFOLFIRINOX or Gem+nab-Paclitaxel alone +/- SBRT (40 Gy/5 fx)
Primary endpoint: locoregional recurrence
🚨SBRT had improved:
✅12 m LRR: 20% vs. 50%
✅mOS 22m vs. 14 m
#ESMO26
Jp Solar Vasconcelos retweeted
By my count, there are 14 clinical trials testing drugs with totally new targets at ESMO.
These include:
The first inhibitor of the (previously undruggable) β-catenin-TCF interaction — Parabalis Medicines.
The first clinical PIP4K2C degrader, triggers metabolic stress — Larkspur Bioscience.
The first clinical TNFR2-targeting (Treg-depleting) antibody, a new immunotherapy strategy — BioInvent.
Full analysis here, just in time for tomorrow! breakingground.substack.com/…
